Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer
Current standard-of-care for patients with pancreatic ductal adenocarcinoma (PDAC) focusses on chemotherapeutic regimens and pancreatic cancer surgery. However, limited treatment options, late diagnosis in advanced tumor stages and the aggressive behavior of PDAC contribute to the high mortality of...
Main Authors: | Ivonne Regel, Julia Mayerle, Mahajan Ujjwal Mukund |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/4/1024 |
Similar Items
-
Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma
by: Ujjwal Mukund Mahajan, et al.
Published: (2021-07-01) -
Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer
by: Andrii Khomiak, et al.
Published: (2020-11-01) -
Molecular Subtyping and Precision Medicine for Pancreatic Cancer
by: Fieke E. M. Froeling, et al.
Published: (2021-01-01) -
Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study
by: Rui Zhao, et al.
Published: (2023-02-01) -
Recent advances in precision medicine for pancreatic ductal adenocarcinoma
by: Hiromitsu Hayashi, et al.
Published: (2021-07-01)